000			01260 a2200337 4500
005			20250514005949.0
264		0	_c20020122
008			200201s 0 0 eng d
022			_a1472-4472
040			_aNLM _beng _cNLM
100	1		_aRevicki, D A
245	0	0	_aCost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. _h[electronic resource]
260			_bCurrent opinion in investigational drugs (London, England : 2000) _cJan 2001
300			_a110-7 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntipsychotic Agents _xeconomics
650	0	4	_aBenzodiazepines
650	0	4	_aClozapine _xtherapeutic use
650	0	4	_aCost-Benefit Analysis
650	0	4	_aDibenzothiazepines _xtherapeutic use
650	0	4	_aHealth Care Costs
650	0	4	_aHumans
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aOlanzapine
650	0	4	_aPirenzepine _xanalogs & derivatives
650	0	4	_aQuetiapine Fumarate
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aRisperidone _xtherapeutic use
773	0		_tCurrent opinion in investigational drugs (London, England : 2000) _gvol. 2 _gno. 1 _gp. 110-7
999			_c11451126 _d11451126